Price Alert

Bio-Rad Laboratories Inc. (BIO)

NYSE: BIO · Real-Time Price · USD

280.09

-5.81 (-2.03%)

At close: Sep 12, 2025, 3:59 PM

280.33

0.09%

After-hours: Sep 12, 2025, 06:50 PM EDT

-2.03% (1D)

Bid	278.05
Market Cap	7.58B
Revenue (ttm)	2.55B
Net Income (ttm)	319.17M
EPS (ttm)	11.09
PE Ratio (ttm)	25.26
Forward PE	25.59
Analyst	Buy

Ask	284.78
Volume	209,649
Avg. Volume (20D)	309,287
Open	284.55
Previous Close	285.90
Day's Range	278.63 - 285.45
52-Week Range	211.43 - 387.99
Beta	0.96

About BIO

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol BIO

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for BIO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Bio-Rad Laboratories Inc. is scheduled to release its earnings on Oct 29, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+17.63%

Bio-Rad Laboratories shares are trading higher aft... Unlock content with Pro Subscription

1 month ago

-3.25%

Bio-Rad Laboratories shares are trading higher after the company reported better-than-expected Q2 financial results.

News

1 week ago · seekingalpha.com

Bio-Rad Laboratories, Inc. (BIO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Bio-Rad Laboratories, Inc. (NYSE:BIO ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 12:45 PM EDT Company Participants Roop Lakkaraju - Executive VP & CFO Norman Schwartz - Chai...

1 week ago · zacks.com

Is it Apt to Hold Bio-Rad Stock in Your Portfolio Now?

BIO's strong ddPCR growth and solid diagnostics demand support its stock despite market pressures and stiff competition.

2 weeks ago · businesswire.com

Bio-Rad's Management to Participate in Upcoming Investor Conferences

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that members of the com...

1 month ago · seekingalpha.com

Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause

The U.S. Government plans to cut the annual budget allocated to the NIH by 40% in 2026. This decision could have an adverse effect on the operations of Bio-Rad. Bio-Rad projects 0.5% revenue growth fo...

1 month ago · fool.com

Bio-Rad (BIO) Q2 EPS Jumps 51%

1 month ago · benzinga.com

Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings

Bio-Rad Laboratories, Inc. BIO reported better-than-expected second-quarter financial results on Thursday.

1 month ago · businesswire.com

Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced today that the company's mana...

1 month ago · seekingalpha.com

Bio-Rad Laboratories, Inc. (BIO) Q2 2025 Earnings Call Transcript

Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q2 2025 Earnings Conference Call July 31, 2025 5:00 PM ET Company Participants Jonathan P. DiVincenzo - President & COO Norman D.